Trial Profile
SOLIRIS (Eculizumab) for the Treatment of Participants With Coronavirus Disease 2019 (COVID-19) - An Expanded Access Protocol
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 06 Nov 2023
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Adult respiratory distress syndrome; COVID-19 respiratory infection
- Focus Expanded access; Therapeutic Use
- Sponsors Alexion AstraZeneca Rare Disease
- 27 Sep 2021 Status changed from recruiting to completed.
- 22 Mar 2021 New trial record